drugset / Trial / NCT02305316

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

NCT02305316

Phase 1 Completed 28 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 14 days or more.

Timeline

Start
2014-02
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 50 mg Oral

Indications